All In MedTech

Device Trial Radar · NCT03433274

Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation

Last checked: Nov 20, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingRandomized with 103 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

103

Actual

Start

Jun 15, 2018

Primary completion

Apr 29, 2024

Study completion Jun 2028

Sponsor

Lead sponsor
Abbott Medical DevicesPublic (ABT)
Sponsor type
Industry
First posted
Feb 14, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Prospective, controlled, multicenter clinical investigation with four trial cohorts: Randomized, Non-repairable, Severe Mitral Annular Calcification (MAC) and Severe Mitral Annular Calcification Continued Access Plan (MAC CAP). Subjects in the Randomized cohort were randomized in a 1:1 ratio to the trial device or to the MitraClip system. Subjects in the Non-repairable, Severe MAC, and Severe MAC CAP cohorts were receive the trial device. The objective of the Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation (SUMMIT) was to evaluate the safety and effectiveness of the Tendyne Transcatheter Mitral Valve System for the treatment of patients with symptomatic, moderate-to-severe or severe mitral regurgitation or for patients with symptomatic mitral valve disease due to severe mitral annular calcification. This randomized controlled trial would provide the opportunity to evaluate the safety and clinical benefits of the Tendyne Transcatheter Mitral Valve System compared to the MitraClip System in patients with symptomatic, moderate-to-severe or severe mitral regurgitation, within approved MitraClip indications. In addition, the safety and effectiveness of the Tendyne Transcatheter Mitral Valve System would be evaluated in patients with severe mitral annular calcification who are at prohibitive risk for mitral valve surgery. Patients who were not suitable for mitral valve surgery for reasons other than severe mitral annular calcification and were also not suitable for transcatheter repair with MitraClip, would be enrolled in the Non-repairable cohort. Subjects would be seen at screening, pre- and post-procedure, discharge, 30 days, 3 months, 6 months, and annually through 5 years.

Conditions

  • Mitral Regurgitation
  • Mitral Insufficiency
  • Mitral Valve Insufficiency
  • Cardiovascular Diseases
  • Valve Disease, Heart
  • Heart Valve Diseases
  • Functional Mitral Regurgitation
  • Degenerative Mitral Valve Disease

Interventions

  • Tendyne Mitral Valve SystemDevice

    Mitral valve replacement

  • MitraClip SystemDevice

    Percutaneous mitral valve repair using the MitraClip system.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Freedom From All-cause Mortality and Heart Failure Hospitalization (HFH)Time frame: 12 months post index procedure

Locations

78 sites in 2 countries. Site status is shown where the registry gives one.

  • Baptist Medical Center Princeton

    Birmingham, Alabama

  • UAB University Hospital

    Birmingham, Alabama

  • Banner-University Medical Center

    Phoenix, Arizona

75 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.